Temple University spinout ThirdLaw Molecular is pioneering a new class of molecules designed to create more effective, faster, and cheaper drugs, writes John George for the Philadelphia Business Journal.
Based in Blue Bell, PA, the company uses its proprietary Spiroligomer technology, developed by founder and president Dr. Christian Schafmeister.
Spiroligomer molecules are synthetic, easy to manufacture, and highly selective in binding to disease-related proteins. Unlike small molecule drugs, which fit into protein pockets and can cause off-target effects, Spiroligomers bind only to their intended targets, reducing side effects. They also penetrate cells like small molecules but maintain the specificity of biologics—without requiring costly intravenous administration.
The company aims to develop therapeutics for cancer and inflammatory diseases while collaborating with larger firms. It has secured $16 million in U.S. Department of Defense grants and $1.5 million in seed funding, with plans to raise an additional $7 million.
The Defense Department is exploring Spiroligomers as antibody replacements for diagnostic tests, while a major pharmaceutical company is currently evaluating a sample library.
Schafmeister named the company after Arthur C. Clarke’s Third Law—“any sufficiently advanced technology is indistinguishable from magic.” He says, “I still want to make magic. I want to make molecules that work like magic.”
Read more about Thirdlaw Molecular in the Philadelphia Business Journal.
